Uncategorized

MENLO PARK, Calif., – Nov 10, 2022 – Today, TIME revealed its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives. We are honored to have GRAIL’s Galleri^® test named among the top inventions of 2022. The Galleri test is a multi-cancer early detection (MCED) test that can detect a

GRAIL continues to drive progress in clinical evidence generation and commercial use of GalleriⓇ, a first-of-its-kind multi-cancer early detection (MCED) blood test. In clinical studies, Galleri has shown the ability to detect more than 50 types of cancer, many of which have no current screening. We are continuing to see momentum in the commercial space,

Jeffrey Venstrom, MD, Chief Medical Officer  |  October 4, 2022 Every year, we lose approximately 600,000 loved ones to cancer.¹ We have been waging a war against cancer for 50 years, and despite remarkable advances, it often feels that cancer is winning. One factor playing a significant role is how we approach screening for cancer. We

GRAIL continues to drive progress in clinical evidence generation and commercial use of GalleriⓇ, a first-of-its-kind multi-cancer early detection (MCED) blood test. In a clinical study, Galleri has shown the ability to detect more than 50 types of cancer, most of which have no current screening. Since sharing interim results last year, GRAIL has completed

Westminster Becomes First Fire Department in Colorado to Offer Galleri Test to Firefighters at High Risk for Cancer Due to Occupational Exposure  MENLO PARK, Calif. and WESTMINSTER, Colo., June 14, 2022 — GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with the

Despite 50 years since waging the war on cancer, it is soon to be the world\’s number one killer. This is because most are detected too late. The status quo in cancer screening is simply unacceptable, as we screen for only five cancers, we look for individual cancers rather than what cancer an individual may

MENLO PARK, Calif., – May 5, 2022 – GRAIL is excited to be named “Best Overall Medical Device Company\’\’ in the 2022 MedTech Breakthrough Awards. GRAIL is a healthcare company with the mission of detecting cancer early, when it can be cured. Our Galleri^® test is the first of-its-kind multi-cancer early detection (MCED) test available

MENLO PARK, CA, May 3, 2022 — We’re honored to be named on Fast Company’s 2022 World Changing Ideas Awards list, which focuses on organizations pursuing innovation for the good of society and the planet. GRAIL, a healthcare company whose mission is to detect cancer early, when it can be cured, received honorable mention for

GRAIL continues to see momentum after launching the GalleriⓇ test last year as a multi-cancer early detection (MCED) test to be available to patients and providers. Galleri has shown the ability to detect more than 50 types of cancer, most of which have no current screening. We remain very pleased by the market\’s reception since